Start
Entdecken
nav.journalClub
Trends
Mehr
synapse
⌘+K
Sprache
Deutsch
Innovations in HER2-targeted therapy: A comprehensive review of trastuzumab deruxtecan | Synapse
March 3, 2026
Innovations in HER2-targeted therapy: A comprehensive review of trastuzumab deruxtecan
HX
Haitong Xie
Sichuan University
XW
Xin Eric Wang
Anhui University
PZ
Peixuan Zhang
Sichuan University
See all
Key Points
Trastuzumab deruxtecan shows enhanced efficacy against HER2-positive cancers and improved patient outcomes.
Recent studies indicate a 60% overall response rate in patients treated with this therapy.
This review summarizes evidence from multiple trials evaluating the effectiveness of trastuzumab deruxtecan against traditional methods.
Advancements in targeted therapy may lead to more personalized treatments in HER2-positive cancer management.
Mark Helpful
Like
Save
Bookmark
Relay
Share
Cite This Study
Copy
Xie et al. (Tue,) studied this question.
synapsesocial.com/papers/69a76069c6e9836116a2d220
https://doi.org/https://doi.org/10.1016/j.bbcan.2026.189550
Mark Helpful
Like
Save
Bookmark
Relay
Share